Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era.
暂无分享,去创建一个
V. Seshan | A. Zelenetz | S. Horwitz | A. Younes | A. Dogan | P. Hamlin | M. Palomba | M. Matasar | J. Yahalom | Anita Kumar | A. Noy | D. Straus | A. Moskowitz | J. Lavery | E. Joffe | P. Caron | D. Sermer | P. Ghione | C. Batlevi | A. Hamilton | S. Bobillo | Gottfried von Keudell | Collette N. Owens | C. Owens
[1] A. Rosenwald,et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial , 2019, The Lancet.
[2] Sonali M. Smith,et al. PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001 , 2019, Blood.
[3] D. Scott,et al. Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC) , 2019, Blood.
[4] M. Ziepert,et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. , 2018 .
[5] R. Houot,et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. , 2018, Blood.
[6] H. Kluin-Nelemans,et al. Relapse in stage I(E) diffuse large B‐cell lymphoma , 2017, Hematological oncology.
[7] Sonali M. Smith,et al. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Byrd,et al. Diffuse Large B-Cell Lymphoma Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] A. Zelenetz,et al. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B‐cell lymphoma in the rituximab era , 2015, British journal of haematology.
[10] Lane F Burgette,et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.
[11] L. Sehn. Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma , 2012, Cancer journal.
[12] A. López-Guillermo,et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[14] Christine F. Wogan,et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Gascoyne,et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone , 2010, Leukemia & lymphoma.
[16] P. Gaulard,et al. Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors , 2009, American journal of hematology.
[17] L. Rimsza,et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Molina,et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Giné,et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[21] B. Christensen,et al. Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.
[22] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[23] E. Noordijk,et al. Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non‐Hodgkin's lymphomas, according to data in the population‐based registry of the comprehensive cancer centre west , 1998, Cancer.
[24] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[25] 김진석. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. , 2012 .
[26] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[27] S. Cessie,et al. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.